Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022

Source: A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*
2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Watch this on-demand webcast capturing a dynamic workshop in which 3 experts discuss best practices and future directions in the use of BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma.
Matthew S. Davids, MD, MMSc
Anthony Mato, MD, MSCE
Jeff Sharman, MD
Released: November 22, 2022 Expiration: No longer available for credit
Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings